Baird Financial Group Inc. Raises Stake in Teva Pharmaceutical Industries Limited (TEVA)

Baird Financial Group Inc. boosted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 24.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 146,554 shares of the company’s stock after buying an additional 28,373 shares during the period. Baird Financial Group Inc.’s holdings in Teva Pharmaceutical Industries Limited were worth $5,313,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. Sharkey Howes & Javer raised its stake in Teva Pharmaceutical Industries Limited by 21.7% in the second quarter. Sharkey Howes & Javer now owns 2,008 shares of the company’s stock worth $101,000 after buying an additional 358 shares during the last quarter. Hudock Capital Group LLC raised its stake in Teva Pharmaceutical Industries Limited by 37.6% in the second quarter. Hudock Capital Group LLC now owns 2,064 shares of the company’s stock worth $103,000 after buying an additional 564 shares during the last quarter. Washington Trust Bank raised its stake in Teva Pharmaceutical Industries Limited by 2.7% in the third quarter. Washington Trust Bank now owns 2,232 shares of the company’s stock worth $103,000 after buying an additional 58 shares during the last quarter. Kistler Tiffany Companies LLC raised its stake in Teva Pharmaceutical Industries Limited by 14.1% in the third quarter. Kistler Tiffany Companies LLC now owns 2,437 shares of the company’s stock worth $112,000 after buying an additional 302 shares during the last quarter. Finally, JFS Wealth Advisors LLC raised its stake in Teva Pharmaceutical Industries Limited by 139.0% in the third quarter. JFS Wealth Advisors LLC now owns 2,495 shares of the company’s stock worth $115,000 after buying an additional 1,451 shares during the last quarter. Institutional investors and hedge funds own 55.03% of the company’s stock.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down 0.73% on Friday, hitting $35.55. The company had a trading volume of 1,687,118 shares. The company has a 50 day moving average of $34.45 and a 200-day moving average of $42.38. Teva Pharmaceutical Industries Limited has a 12-month low of $31.90 and a 12-month high of $59.35. The company has a market cap of $36.08 billion, a price-to-earnings ratio of 507.86 and a beta of 0.58.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings data on Monday, February 13th. The company reported $1.38 EPS for the quarter, beating the Zacks’ consensus estimate of $1.36 by $0.02. Teva Pharmaceutical Industries Limited had a net margin of 1.50% and a return on equity of 17.46%. The business had revenue of $6.25 billion for the quarter, compared to analyst estimates of $6.26 billion. During the same quarter last year, the business earned $1.32 earnings per share. The business’s revenue for the quarter was up 33.0% on a year-over-year basis. On average, analysts forecast that Teva Pharmaceutical Industries Limited will post $4.75 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 20th. Investors of record on Thursday, March 2nd will be paid a dividend of $0.34 per share. The ex-dividend date is Tuesday, February 28th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.80%. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently 1,657.38%.

“Baird Financial Group Inc. Raises Stake in Teva Pharmaceutical Industries Limited (TEVA)” was first published by Mideast Time and is the sole property of of Mideast Time. If you are accessing this article on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this article can be accessed at https://www.mideasttime.com/baird-financial-group-inc-raises-stake-in-teva-pharmaceutical-industries-limited-teva/1541344.html.

TEVA has been the topic of a number of recent research reports. Mizuho lowered Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and reduced their target price for the company from $64.00 to $45.00 in a research note on Monday, October 24th. Credit Suisse Group raised Teva Pharmaceutical Industries Limited from a “neutral” rating to an “outperform” rating and reduced their target price for the company from $59.00 to $52.00 in a research note on Monday, October 31st. They noted that the move was a valuation call. HSBC Holdings plc lowered Teva Pharmaceutical Industries Limited from a “buy” rating to a “hold” rating and upped their target price for the company from $44.00 to $66.00 in a research note on Friday, November 4th. Bank of America Corporation lowered Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and set a $48.00 target price on the stock. in a research note on Monday, November 7th. Finally, Barclays PLC initiated coverage on Teva Pharmaceutical Industries Limited in a research note on Monday, November 14th. They issued an “equal weight” rating and a $46.00 target price on the stock. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and sixteen have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $50.42.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.